Exercising for 150 minutes each week may be the best treatment for Alzheimer’s, according to a study published in the Journal of Alzheimer’s Disease. Researchers from the University of Maryland School of Public Health conducted the study, which reveals that exercise could improve cognitive function in people at risk of Alzheimer’s by improving the efficiency of brain activity… …read more
Filed under: Investing
Amarantus BioScience Appoints Mark Benedyk, Ph.D., to Board of Directors
SUNNYVALE, Calif.–(BUSINESS WIRE)– Amarantus BioScience, Inc. (OTCQB: AMBS), a biotechnology company discovering and developing treatments and diagnostics for diseases associated with neurodegeneration and apoptosis centered around its patented therapeutic protein Mesencephalic Astrocyte Neurotrophic Factor (MANF), has appointed Mark Benedyk, Ph.D., to its Board of Directors. Dr. Benedyk has over 18 years of experience as a senior business development executive and consultant to life science companies, and has served as a Corporate Advisor to Amarantus since 2011. With the addition of Dr. Benedyk, the Amarantus board has four members, two of whom are considered independent directors, including Dr. Benedyk.
“I am excited to join the Amarantus board at such an important stage of the Company’s scientific and business development growth,” said Dr. Benedyk. “I look forward to helping the Company as it advances MANF towards the clinic for Parkinson’s disease, and executes a commercial strategy for its promising clinical diagnostic tests for Parkinson’s and Alzheimer’s disease.”
Gerald E. Commissiong, President and Chief Executive Officer of Amarantus BioScience, stated “Mark Benedyk has played a significant role in the growth and success of several leading healthcare companies. With his knowledge and understanding of clinical development and regulatory affairs, as well as the financial and operating requirements of a development-stage company, Mark will be an important resource for all aspects of managing our progress and creating value for shareholders.”
Dr. Benedyk is currently a Managing Partner at Rila Partners LLC, a business and corporate development consultancy. In this role he serves on the Strategic Advisory Board of KemPharm, Inc., is a Director at the Center for Drug Research and Development Ventures, Inc., and is a member of the Translational Medicine Advisory Board of the CNS Regenerative Medicine Foundation. Previously he was head of The Pfizer Incubator (TPI) where his duties included membership on the TPI Board of Directors, board positions with TPI portfolio companies, oversight of the TPI operations team, and reviewing investment opportunities in multiple technologies.
Dr. Benedyk has held executive business development roles at Ascenta Therapeutics, Optimer Pharmaceuticals, Aurora Biosciences (acquired by Vertex Pharmaceuticals), and Elan Pharmaceuticals, where he led partnering efforts for several key clinical-stage products for the treatment of Alzheimer’s Disease, migraine and other neurological indications. He received his Ph.D. in Developmental and Molecular Genetics from The Rockefeller University, and Bachelor of Science degree in Microbiology and Botany from the University of Michigan.
About Amarantus BioScience
Filed under: Investing
Every quarter, many money managers have to disclose what they’ve bought and sold, via “13F” filings. Their latest moves can shine a bright light on smart stock picks.
Today, let’s look at the D. E. Shaw company, founded by David E. Shaw and with a reportable stock portfolio totaling $41 billion in value as of Dec. 31, 2012.
Shaw is known as a math wizard and a quantitative investing pioneer. His firm is reportedly extremely selective, hiring less than 1% of applicants — and Amazon.com CEO Jeff Bezos once made the cut.
So what does D. E. Shaw’s latest quarterly 13F filing tell us? Here are a few interesting details:
The biggest new holdings are Kraft Foods Group and ADT. Other new holdings of interest include Spectrum Pharmaceuticals . Spectrum has been experiencing strong growth due to the success of its colorectal cancer drug Fusilev, but that was partly due to a supply shortage faced by generic competitors. With that issue going away, Spectrum recently trimmed its growth expectations, sending the heavily shorted stock down sharply. Still, it has more than a dozen other drugs in development in its pipeline, and has broadened its scope with the recent purchase of Allos Therapeutics, which is expected to help cut costs and also includes the lymphoma drug Folotyn. Spectrum also recently secured rights for the bladder-cancer drug apaziquone.
Among holdings in which D. E. Shaw increased its stake was Acadia Pharmaceuticals , which has tripled in value over the past year, on high hopes for its pimavanserin drug, which treats psychosis in patients with Parkinson’s disease and is nearing the phase 3 trial finish line. If the drug gains FDA approval, it will enjoy little competition and could be a big winner for Acadia. The company thinks the drug also might be effective against psychosis related to Alzheimer’s Disease and is conducting trials for that as well.
D. E. Shaw reduced its stake in lots of companies, including Mesabi Trust and Molycorp . With a recent hefty dividend yield of 8.2%, Mesabi Trust is a royalty trust collecting a cut of the proceeds from iron mined by a Cliffs Natural Resources subsidiary — and then paying them out to shareholders. Unlike many companies with fixed payouts, Mesabi’s fluctuate over time, along with the fortunes of the mines, and while royalty trusts often have expiration dates, Mesabi’s expiration isn’t happening anytime soon. A possible downside for the stock is a slowdown in demand for ore, particularly in China, which has been one of several issues for Cliffs.
Molycorp has been struggling in a tough environment and recently worried investors with a surprisingly large share offering and debt issuance. (Some worry about further capital needs, too, and don’t like its negative free cash flow.) Still, for those who can accept considerable risk and volatility, there’s a lot of promise in Molycorp, in part due to its acquisition of Neo Materials …read more
Source: FULL ARTICLE at DailyFinance
Damage to small blood vessels in the brain could be a secondary risk factor leading to Alzheimer’s Disease, a new study in JAMA Neurology suggests. A part of this blood vessel damage is known as white matter hyperintensities, seen in the brains of Alzheimer’s patients and appearing to increase the risk for the disease, making it a secondary factor… …read more
Source: FULL ARTICLE at Medical News Today